ISA101b
Sponsors
M.D. Anderson Cancer Center, ISA Pharmaceuticals, Dan Zandberg, Regeneron Pharmaceuticals
Conditions
Cervical CancerHPV-Related Squamous Cell CarcinomaHPV16 PositiveHead and Neck Squamous Cell CarcinomaMalignant Neoplasms of Ill-defined Secondary and Unspecified SitesMalignant Neoplasms of Lip Oral Cavity and PharynxOropharyngeal CancerSquamous Cell Carcinoma of the Oropharynx
Phase 2
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
TerminatedNCT03258008
Start: 2018-04-04End: 2021-11-05Updated: 2022-12-16
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
NCT03669718
Start: 2018-11-30End: 2025-06-30Target: 194Updated: 2023-12-29
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for Intermediate Risk HPV-16-associated Head and Neck Squamous Cell Carcinoma
Active, not recruitingNCT04369937
Start: 2020-07-06End: 2026-01-15Target: 18Updated: 2025-09-11
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
Active, not recruitingNCT04398524
Start: 2021-07-01End: 2024-12-30Target: 65Updated: 2024-01-16
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
CompletedNCT04646005
Start: 2021-06-28End: 2024-05-29Updated: 2025-09-08